Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2017-12-27 M&A Activity
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
要约收购报告书摘要
M&A Activity Classification · 100% confidence The document is titled as a "要约收购报告书摘要" which translates to "Summary of Tender Offer Report" or "Offer to Purchase Report Summary." It details a comprehensive tender offer by CITIC Capital Holdings Limited and its subsidiaries to acquire shares of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) listed on the Shanghai Stock Exchange. The document includes detailed information about the offeror, the target company, shareholding structures, the purpose of the offer, regulatory approvals needed, offer price, funding, and legal advisors. It is a formal disclosure related to a takeover bid or acquisition proposal. The content is consistent with filings related to M&A activity, specifically tender offers and takeover bids. It is not an annual report, earnings release, or other financial report. It is a detailed announcement and report on a merger and acquisition activity. Therefore, the appropriate classification is "M&A Activity" with code TAR.
2017-12-27 Chinese
关于重大资产重组继续停牌暨进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding the continuation of a trading suspension due to a major asset restructuring. It details the progress, reasons for the suspension, approvals needed, and expected timelines. It references multiple prior announcements and progress updates but does not contain actual financial statements or detailed financial data. The document is primarily an update on the status of a major asset restructuring and the related stock suspension, not the restructuring report itself. Therefore, it fits best as a Capital/Financing Update (CAP) since it concerns significant corporate financing and restructuring activities and stock trading suspension related to that.
2017-12-27 Chinese
2017年第三次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2017 third extraordinary general meeting (临时股东大会) of Harbin Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting's procedures and voting outcomes. The document does not contain financial statements or management discussion of financial results, nor is it a report publication announcement. It is a legal opinion related to a shareholder meeting and voting results. This fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides official confirmation and legal opinion on the voting results of a shareholder meeting.
2017-12-26 Chinese
2017年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2017 third extraordinary shareholders' meeting (临时股东大会决议公告). It details the meeting date, attendance, voting results on a specific proposal regarding a major asset restructuring suspension, and legal witness statements confirming the legality and validity of the meeting and voting process. There is no indication that this is a full report or financial statement; rather, it is an official announcement of the voting results from a shareholders' meeting. The document length is short (1480 characters), and it focuses on voting outcomes and meeting procedural details. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-12-26 Chinese
重大事项进展及提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from 哈药集团股份有限公司 regarding a significant corporate event involving potential changes in the controlling shareholder and related equity restructuring. It mentions stock suspension due to the uncertainty of the event and references previous announcements about the progress of the matter. The content focuses on informing investors about the ongoing situation, regulatory compliance, and potential impact on control and tender offer obligations. There are no financial statements, detailed financial data, or comprehensive reports included. The document is relatively short (1109 characters) and serves as a progress and cautionary announcement about a major corporate event rather than a full report or detailed filing. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2017-12-22 Chinese
关于控股股东股权结构变动的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a short announcement (1818 characters) regarding a change in the equity structure of the controlling shareholder of 哈药集团股份有限公司. It details the transfer of shares among related parties but explicitly states that the controlling shareholder and actual controller remain unchanged. There are no financial statements, no detailed financial performance data, and no mention of a report being attached or published. The content is focused on notifying the market about a change in shareholding structure of the controlling shareholder, which fits the definition of a Major Shareholding Notification (MRQ). It is not a full report, nor an earnings release or management report. Therefore, the appropriate classification is MRQ with high confidence.
2017-12-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.